SCHWARTZ, PETER
 Distribuzione geografica
Continente #
NA - Nord America 20.008
AS - Asia 15.832
EU - Europa 12.248
SA - Sud America 1.983
AF - Africa 435
OC - Oceania 48
Continente sconosciuto - Info sul continente non disponibili 21
Totale 50.575
Nazione #
US - Stati Uniti d'America 19.612
CN - Cina 8.565
SG - Singapore 3.344
IE - Irlanda 2.607
UA - Ucraina 2.031
DE - Germania 1.820
HK - Hong Kong 1.546
BR - Brasile 1.476
FI - Finlandia 1.190
RU - Federazione Russa 1.114
VN - Vietnam 1.080
SE - Svezia 903
IT - Italia 872
FR - Francia 752
GB - Regno Unito 589
IN - India 269
CA - Canada 232
BD - Bangladesh 204
ZA - Sudafrica 177
AR - Argentina 169
IQ - Iraq 149
MX - Messico 99
JP - Giappone 97
EC - Ecuador 79
PK - Pakistan 72
CO - Colombia 71
NL - Olanda 71
VE - Venezuela 70
TR - Turchia 69
MA - Marocco 61
ID - Indonesia 54
AT - Austria 49
ES - Italia 48
BE - Belgio 47
PH - Filippine 47
PL - Polonia 41
UZ - Uzbekistan 40
CL - Cile 38
SA - Arabia Saudita 36
KE - Kenya 35
PY - Paraguay 33
TN - Tunisia 33
MU - Mauritius 32
MY - Malesia 31
AU - Australia 29
JO - Giordania 29
EG - Egitto 26
AE - Emirati Arabi Uniti 24
IR - Iran 22
AZ - Azerbaigian 21
NP - Nepal 19
PE - Perù 19
EU - Europa 17
IL - Israele 17
DZ - Algeria 16
NZ - Nuova Zelanda 16
BO - Bolivia 15
ET - Etiopia 15
CR - Costa Rica 14
OM - Oman 13
UY - Uruguay 12
AL - Albania 11
KZ - Kazakistan 11
NI - Nicaragua 10
CZ - Repubblica Ceca 9
LT - Lituania 9
LV - Lettonia 9
RO - Romania 9
SN - Senegal 9
BG - Bulgaria 8
KR - Corea 8
LB - Libano 8
PS - Palestinian Territory 8
PT - Portogallo 8
DK - Danimarca 7
HU - Ungheria 7
JM - Giamaica 7
PA - Panama 7
RS - Serbia 7
CH - Svizzera 6
KG - Kirghizistan 6
TH - Thailandia 6
TT - Trinidad e Tobago 6
DO - Repubblica Dominicana 5
GE - Georgia 5
GR - Grecia 5
KW - Kuwait 5
QA - Qatar 5
HN - Honduras 4
AM - Armenia 3
BH - Bahrain 3
BW - Botswana 3
CG - Congo 3
HR - Croazia 3
MD - Moldavia 3
NO - Norvegia 3
PR - Porto Rico 3
SY - Repubblica araba siriana 3
ZW - Zimbabwe 3
AO - Angola 2
Totale 50.515
Città #
Chandler 2.645
Dublin 2.602
Jacksonville 2.590
Nanjing 2.101
San Jose 1.931
Ashburn 1.608
Singapore 1.563
Dallas 1.514
Hong Kong 1.510
Beijing 975
Boardman 905
Nanchang 853
Princeton 640
Lawrence 603
Shenyang 600
Changsha 576
Hebei 571
Wilmington 559
Lauterbourg 540
Jiaxing 511
Munich 482
Helsinki 425
Medford 408
Los Angeles 403
Ho Chi Minh City 378
Tianjin 331
Hangzhou 326
Hanoi 261
Moscow 232
Redondo Beach 224
Council Bluffs 217
Buffalo 212
Ann Arbor 195
New York 178
Milan 156
Woodbridge 148
Johannesburg 138
São Paulo 137
Shanghai 133
Verona 120
Norwalk 112
Santa Clara 98
Tokyo 92
Orem 85
Toronto 81
Houston 74
Frankfurt am Main 71
Nuremberg 70
Seattle 65
Baghdad 64
Fairfield 61
Kunming 59
Des Moines 57
Brooklyn 56
Pavia 53
Zhengzhou 53
Guangzhou 52
Mcallen 52
Chennai 50
San Francisco 50
Washington 48
Chicago 46
Da Nang 44
Falkenstein 44
Jinan 44
Falls Church 42
Haiphong 38
Montreal 37
Montréal 37
Brussels 36
Denver 36
London 36
Ningbo 36
Tashkent 36
Warsaw 36
Rome 34
Belo Horizonte 33
Nairobi 33
Rio de Janeiro 33
Atlanta 32
Boston 32
Brasília 32
Stockholm 32
Turku 32
Curitiba 29
Guayaquil 29
Manchester 29
Mexico City 29
Phoenix 29
The Dalles 29
Caracas 28
Amman 27
Dhaka 26
Amsterdam 25
Biên Hòa 24
Fuzhou 24
Lahore 24
City of London 23
Dearborn 23
Pune 22
Totale 33.165
Nome #
[A new experimental model for the study of arrhythmias dependent on the interaction between myocardial ischemia and sympathetic hyperactivity. I. Effects of phosphocreatinine]. 301
[Legal implications of medical guidelines. A Task Force of the European Society of Cardiology]. 268
[Changes of a reflex nature in the cardiac sympathetic activity induced with increases of arterial pressure in spinal animals]. 268
[Idiopathic syndrome of the long QT interval--the need for a prospective study]. 262
Identificazione di microRNA circolanti specificatamente sovra espressi in corso di infarto miocardico acuto. 251
Vagus nerve stimulation: from pre-clinical to clinical application: challenges and future directions. 251
Calcio antagonisti e aritmie da riperfusione miocardica 205
Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. 186
Pathophysiological rationale for cardiac vagal denervation in the treatment of atrial fibrillation 168
Long QT and short QT syndromes. 160
[Activity of preganglionic sympathetic single fibers during experimental coronary occlusion]. 152
[Activity of afferent cardiac vagal fibers during experimental myocardial ischemia]. 149
[Infant mortality and sudden crib death in Lombardy]. 147
[Neonatal electrocardiography and the sudden infant death syndrome (SIDS)]. 146
A KCNH2 branch point mutation causing aberrant splicing contributes to an explanation of genotype-negative long QT syndrome. 146
Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice 143
PREDESTINATION: PRimary vEntricular fibrillation and suDden dEath during a firST myocardIal iNfArcTION: Genetic basis. 143
Identification of a KCNQ1 polymorphism acting as a protective modifier against arrhythmic risk in long-QT syndrome. 137
Spectrum and prevalence of mutations involving BrS1-12 susceptibility genes in a cohort of unrelated patients referred for Brugada Syndrome genetic testing: implications for genetic testing. 136
[Idiopathic ventricular fibrillation: from a collection of clinical cases to a prospective evaluation. The U-CARE Steering Committee. Unexplained Cardiac Arrest Registry of Europe]. 136
[Electrophysiologic features of the modulation of ATP-dependent potassium channels]. 135
FGF12 is a candidate Brugada syndrome locus. 133
25th anniversary of the International Long-QT Syndrome Registry: an ongoing quest to uncover the secrets of long-QT syndrome. 132
Aspetti elettrofisiologici della modulazione dei canali del potassio ATP-dipendenti 131
Multiscale complexity analysis of the cardiac control identifies asymptomatic and symptomatic patients in long QT syndrome type 1. 131
[Long QT syndrome and Brugada syndrome: 2 aspects of the same disease?]. 128
[Study of preganglionic sympathetic single fibers in relation to various physiologic and pathologic stimuli]. 128
Antifibrillatory efficacy of ersentilide, a novel beta-adrenergic and Ikr blocker, in conscious dogs with a healed myocardial infarction. 128
A Molecular Link between the Sudden Infant Death Syndrome and the Long-QT Syndrome. 127
Alpha 1-adrenergic blockade and sudden cardiac death. 126
Autonomic mechanisms and sudden death. New insights from analysis of baroreceptor reflexes in conscious dogs with and without a myocardial infarction. 126
Long QT syndrome-associated mutations in intrauterine fetal death. 126
Effect of Considering the Relatives' Quality of Life in Cost-Utility Studies 126
Linee Guida. Task Force sulla Morte Cardiaca Improvvisa, Società Europea di Cardiologia. Riassunto delle raccomandazioni 124
Sympathetic activation, ventricular repolarization and Ikr blockade: implications for the antifibrillatory efficacy of potassium channel blocking agents 123
Novel human pathological mutations. Gene symbol: SCN5A. Disease: Brugada Syndrome. 122
[Cardio-cardiac sympathico-vagal reflex]. 121
[Sympathetic reflex induced by experimental coronary occlusion]. 120
Cardiac arrhythmias of genetic origin are important contributors to Sudden Infant Death Syndrome. 118
Electrocardiographic and genetic screening for long QT syndrome: results from a prospective study on 44,596 neonates. 118
Risk stratification in the Long-QT Syndrome 118
Role of common and rare variants in SCN10A: results from the Brugada syndrome QRS locus gene discovery collaborative study 118
QT prolongation and sudden infant death syndrome - from theory to evidence. 118
[Evaluation of flecainide in the therapy of chronic ventricular arrhythmia using the acute oral load method]. 118
Cost-effectiveness of Neonatal ECG as a Screening for Long QT-syndrome: A Decision Analysis Approach. 117
A Recessive Variant of the Romano-Ward Long QT Syndrome 116
The genetics underlying acquired long QT syndrome: impact for genetic screening. 116
Elucidating arrhythmogenic mechanisms of long-QT syndrome CALM1-F142L mutation in patient-specific induced pluripotent stem cell-derived cardiomyocytes 115
Inherited cardiac arrhythmia syndrome. Role of potassium channels 114
An experimental approach to the choice of antiarrhythmic therapy. 114
A novel rare variant in SCN1Bb linked to Brugada syndrome and SIDS by combined modulation of Na(v)1.5 and K(v)4.3 channel currents. 114
Cardiac potassium channel dysfunction in sudden infant death syndrome. 113
Adrenergic Arrhythmogenesis and The Long QT syndrome 113
Arrhythmogenic disorders of genetic origin. Long QT Syndrome: from genetics to management. 113
A novel disease gene for Brugada syndrome: sarcolemmal membrane-associated protein gene mutations impair intracellular trafficking of hNav1.5. 113
[Baroceptive reflex sensibility in non-anesthetized animals. Evaluation and comparison of 2 methods applicable to humans]. 113
Genotype-Phenotype correlation in the Long QT Syndrome. Gene-specific triggers for life-threatening arrhythmias 112
The LQT2 KCNH2-Q376Q splicing muation: functional characterization, molecular correction and therapeutic implication. 112
All LQT3 patients need an ICD. True or false? 112
QT prolongation, sudden death, and sympathetic imbalance: the pendulum swings. 112
Cardiac sodium channel dysfunction in sudden infant death syndrome. 112
[Neural mechanisms of sudden death]. 112
Farmaci antipsicotici, QT lungo, morte improvvisa e rischio cardiovascolare. Il cardiologo incontra lo psichiatra 112
Generation of the human induced pluripotent stem cell (hiPSC) line PSMi005-A from a patient carrying the KCNQ1-R190W mutation 112
Genetic Modifiers for the Long-QT Syndrome: How Important Is the Role of Variants in the 3′ Untranslated Region of KCNQ1? 112
Generation of the human induced pluripotent stem cell (hiPSC) line PSMi002-A from a patient affected by the Jervell and Lange-Nielsen syndrome and carrier of two compound heterozygous mutations on the KCNQ1 gene 112
Autonomic nervous system and sudden cardiac death. Experimental basis and clinical observations for post-myocardial infarction risk stratification. 111
A common polymorphism associated with antibiotic-induced cardiac arrhythmia 111
Unexplained cardiac arrest. The need for a prospective registry. 111
Generation of the human induced pluripotent stem cell (hiPSC) line PSMi007-A from a Long QT Syndrome type 1 patient carrier of two common variants in the NOS1AP gene 111
ALIVE Investigators: The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial. 110
[Sudden death after myocardial infarction. Prediction based on the baroreceptor reflex]. 109
Autonomic nervous system, myocardial ischemia, and malignant ventricular arrhythmias: Experimental findings 109
Ranolazine in the treatment of atrial fibrillation: Results of the dose-ranging RAFFAELLO (ranolazine in atrial fibrillation following an electrical cardioversion) study 109
QT lungo, sindrome del 108
Mortalità infantile e morte improvvisa in culla in Lombardia 108
Baroreflex sensitivity predicts long-term cardiovascular mortality after myocardial infarction even in patients with preserved left ventricular function. 108
Autonomic Modulation for the Management of Patients with Chronic Heart Failure 108
Identification of a targeted and testable antiarrhythmic therapy for long-QT syndrome type 2 using a patient-specific cellular model 108
Generation of the human induced pluripotent stem cell (hiPSC) line PSMi003-A from a patient affected by an autosomal recessive form of Long QT Syndrome type 1 108
Rapid heart rate increase at onset of exercise predicts adverse cardiac events in patients with coronary artery disease 107
KCNH2-K897T Is a Genetic Modifier of Latent Congenital Long-QT Syndrome. 106
[Long-QT caused by drugs and torsade de pointes: a genetic basis?]. 106
The long QT syndrome. Prospective longitudinal study of 328 families. 106
Age and sex-related differences in the clinical manifestations of congenital long QT syndrome: findings from the International Prospective LQTS Registry 106
Baroreceptor reflexes and sudden cardiac death: experimental findings and background. 106
Autonomic nervous system and arrhythmias. 105
A molecular basis for the therapy of the long QT syndrome 105
Atrial fibrillation requiring urgent medical care. Approach and outcome in the various departments of admission. Data from the atrial Fibrillation/flutter Italian REgistry (FIRE). 105
From patient-specific induced pluripotent stem cells to clinical translation in long QT syndrome Type 2 105
Prevalence of the congenital long-QT syndrome. 104
Spectrum of ST-T-wave patterns and repolarization parameters in congenital long-QT syndrome: ECG findings identify genotypes 103
Individual autonomic profile contributes to the risk for life-threatening arrhythmias among KCNQ1-A341V mutation carriers 103
The KCNH2-IVS9-28A/G mutation causes aberrant isoform expression and hERG trafficking defect in cardiomyocytes derived from patients affected by Long QT Syndrome type 2 103
An International Multi-Center Evaluation of Type 5 Long QT Syndrome: A Low Penetrant Primary Arrhythmic Condition. 103
Legal implications of medical guidelines. A task Force of the European Society of Cardiology 102
Phenotypic variability and unusual clinical severity of congenital long-QT syndrome in a founder population. 102
K+ channel blockade in the prevention of ventricular fibrillation in dogs with acute ischemia and enhanced sympathetic activity. 102
The ICD for the long QT syndrome: which indications, complications, and results? 101
Update of the guidelines on sudden cardiac death of the European Society of Cardiology 101
Totale 12.851
Categoria #
all - tutte 210.804
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 210.804


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021109 0 0 0 0 0 0 0 0 0 0 0 109
2021/20222.401 31 10 72 28 34 176 30 129 173 67 390 1.261
2022/20237.639 921 455 58 608 836 888 6 456 3.103 34 170 104
2023/20242.416 259 528 108 197 280 647 52 128 7 67 69 74
2024/20257.226 120 683 194 251 110 284 617 756 1.604 222 627 1.758
2025/202615.599 1.114 1.197 2.185 1.436 1.632 756 3.152 637 1.278 1.197 707 308
Totale 50.859